This is a repository copy of *The reversal of anticoagulation in clinical practice*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/135344/

Version: Published Version

**Article:**
Thomas, S. and Makris, M. orcid.org/0000-0001-7622-7939 (2018) The reversal of anticoagulation in clinical practice. Clinical Medicine, 18 (4). pp. 314-319. ISSN 1470-2118

https://doi.org/10.7861/clinmedicine.18-4-314

© Royal College of Physicians 2018. Reproduced in accordance with the publisher's self-archiving policy.

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
The reversal of anticoagulation in clinical practice

Authors: Sally ThomasAB and Michael MakrisCD

Widespread use of anticoagulant drugs for treatment and prevention of thromboembolic events means it is common to encounter patients requiring reversal of anticoagulation for management of bleeding or invasive procedures. While supportive and general measures apply for patients on all agents, recent diversification in the number of licensed agents makes an understanding of drug-specific reversal strategies essential. Recognising effects upon, and limitations of, laboratory measures of coagulation also plays an important role. An understanding of reversal strategies alone is insufficient to competently care for patients who may require anticoagulation reversal. It is also necessary to reduce the need for reversal through correct prescribing and by employing appropriate periprocedural bridging strategies for elective and semi-elective procedures. Finally, consideration of whether and when to reintroduce an anticoagulant drug following reversal is important not only to balance bleeding and thrombotic risks for individual patients but also for timely management of discharge.

Introduction

Since the earliest clinical investigation of heparin in the 1930s,1 the indications for anticoagulant drugs and the number of commonly encountered agents has increased (Table 1). These drugs act by inhibiting different stages of the coagulation cascade that culminates in the formation of cross-linked fibrin (Fig 1). It is common in clinical practice to encounter patients requiring anticoagulation reversal. Indications for anticoagulation reversal include:

- bleeding
- elective or emergency invasive procedures or surgery
- over-anticoagulation, due to accidental or intentional overdose, drug interactions or reduced excretion.

A decision to reverse anticoagulation must weigh the benefits of anticoagulation reversal in terms of stopping bleeding or reduction of bleeding risk against the risk of development or extension of thrombosis while anticoagulation is reversed. This can be particularly challenging in situations such as bleeding in patients with mechanical heart valves.

This article will focus on urgent reversal of anticoagulation. It is important that care of patients on anticoagulant drugs is optimised so that the need for urgent reversal is minimised. The benefits should be weighed against a patient’s individual bleeding risk when deciding to anticoagulate and in choice of anticoagulant, and factors including potential drug–drug interactions and the need for dose reduction considered.2 Anti-platelet agents should be discontinued when an anticoagulant is used, except in certain circumstances.3 An anticoagulation plan should be prepared in advance of elective procedures so that urgent reversal is not required. Table 2 summarises the length of time for which different anticoagulants should be stopped prior to an invasive procedure. Some procedures (eg joint injections, Key points

The type of anticoagulant, dose, timing of last dose and indication are significant points to establish when making decisions about anticoagulation reversal.

For elective procedures and surgery, the need for anticoagulation reversal should be avoided by determining whether cessation of anticoagulant is required, and by following local bridging protocols.

In patients bleeding while on anticoagulants, supportive treatment including blood components and local measures should be employed alongside the steps taken to reverse the anticoagulant effect.

INR and APTT can be used to assess anticoagulant activity of vitamin K antagonists and unfractionated heparin respectively, but therapeutic ranges for these drugs cannot be used to interpret clotting tests in patients on other anticoagulants.

Specific reversal agents exist for vitamin K antagonists (vitamin K and prothrombin complex concentrate), heparins (protamine sulphate) and dabigatran (Idarucizumab) but there is currently no specific reversal agent for fondaparinux or for the oral factor Xa inhibitors.

KEYWORDS: anticoagulants, direct acting oral anticoagulants, reversal, haemorrhage, surgery.
endoscopic procedures with a low risk of bleeding and cataract surgery) can be performed without stopping anticoagulants. If anticoagulation is not lifelong, consideration should be given to deferring the procedure until treatment is completed. If anticoagulant treatment must be interrupted, bridging protocols should be employed that take into account drug pharmacokinetics and bleeding and the thrombotic risk.

In urgent situations where reversal is required a combination of general measures which apply regardless of which anticoagulant a patient is taking, and drug-specific management is used. Drug specific reversal strategies are summarised in Table 3. General measures include making an assessment of the dose and timing of the drug, considering its rate of elimination, and in the case of bleeding resuscitating the patient and identifying and treating the source of bleeding. The efficacy and evidence base for specific reversal strategies varies between anticoagulants, and an understanding of this, is important when making choices about reversal.

**General measures for anticoagulation reversal**

**Baseline information and investigations**

It is important to establish what anticoagulant a patient is taking, the dose, frequency, timing of last dose and indication. The anticoagulant should be stopped. Other drugs that can affect bleeding (eg antiplatelet agents and non-steroidal anti-inflammatory drugs) should also be noted. Blood tests must include a full blood count and clotting screen (prothrombin time [PT], activated partial thromboplastin time [APTT], thrombin time [TT] and fibrinogen). Additional clotting samples for drug-specific tests may be requested, guided by discussion with haematology or the coagulation laboratory. Liver function tests and renal function tests are essential to provide information on drug elimination.

**Supportive measures**

Bleeding patients should receive appropriate resuscitation and blood-component support, which in the situation of major haemorrhage should follow national guidelines.3

**Pharmacological measures**

Tranexamic acid 1 g every 8 hours should be considered for patients requiring reversal of anticoagulation. Tranexamic acid is beneficial in patients bleeding following trauma, although these actions include making an assessment of the dose and timing of the drug, considering its rate of elimination, and in the case of bleeding resuscitating the patient and identifying and treating the source of bleeding. The efficacy and evidence base for specific reversal strategies varies between anticoagulants, and an understanding of this, is important when making choices about reversal.

---

**Table 1. Key pharmacokinetic features of common anticoagulant drugs**

| Name            | Excretion                       | Plasma half-life |
|-----------------|---------------------------------|------------------|
| Warfarin        | Hepatic metabolism to inactive metabolites excreted in urine | Effective half-life 40 h |
| UFH             | Rapid endothelial cell internalisation (saturatable), slower renal clearance | 45–90 min |
| LMWH            | Predominantly renal             | 4 h              |
| Fondaparinux    | 70% renal                      | 17–21 h          |
| Argatroban      | Hepatic                        | 13 h             |
| Dabigatran      | 80% renal                      | 12 h             |
| Apixaban        | 25% renal, 75% hepatic         | 10–14 h          |
| Edoxaban        | 35% renal, 65% hepatic         | 5–9 h            |
| Rivaroxaban     | 25% renal, 75% hepatic         |                  |

LMWH = low-molecular-weight heparin; UFH = unfractionated heparin

---

**Fig 1. Representation of stage of action of anticoagulants and their reversal agents on a schematic clotting cascade.** This diagram is intended to summarise drug actions but does not reflect the complexity of haemostasis believed to occur physiologically, where cell surface molecules regulate initiation, amplification and propagation of thrombus.11 Please see the main text for details on specific drug and reversal agent mechanisms. PCC = prothrombin complex concentrate; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; → = promotes; ⊥ = suppresses
drug elimination and excretion route and elimination time (Table 1) suggest the drug has been cleared, specific reversal agents should not be employed. Haemodialysis and haemofiltration have little utility in anticoagulant reversal.

Specific management

**Vitamin K antagonists**

Vitamin K antagonists exert their anticoagulant effect by inhibiting the vitamin K-dependent carboxylation of coagulation factors II, VII, IX and X (Fig 1). In the UK, warfarin is the most commonly prescribed vitamin K antagonist and we will focus on reversal of warfarin in this article. Acenocoumarol and phenindione may be encountered, and urgent reversal of all three agents follows similar principles.

Where cessation or dose-reduction is insufficient, reversal can be achieved with oral or intravenous vitamin K or by replacement of the affected factors, a choice determined by the desired rapidity and depth of reversal.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.

In patients with a moderately elevated international normalised ratio (INR) (5–8) without bleeding, reversal is usually achieved by withholding one or two doses of warfarin, followed by dose reduction. INRs above 8 confer a substantially increased bleeding risk so anticoagulation should be reversed with oral vitamin K 1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 when additional bleeding risk factors are present.
produce a good correction of the INR and are not recommended. 10 PCC is superior to fresh-frozen plasma in achieving rapid correction of INR in patients with bleeding 11 and those requiring urgent warfarin reversal for surgery or procedures. 12 5 mg vitamin K should be given concurrently to maintain reversal when factor levels fall. PCCs should be avoided outside emergency situations; they carry risks associated with plasma-derived products (such as viral infection) and are associated with a risk of thrombosis. The limited data on thrombosis suggests the risk is relatively low and it is difficult to distinguish from other patient risk factors. 13,14 Nonetheless, caution is advised in patients with recent thrombosis or surgery, cardiovascular disease, or liver disease.

Unfractionated heparin

Unfractionated heparin (UFH) enhances the activity of antithrombin, an endogenous negative regulator of the clotting cascade that inactivates thrombin and factor Xa (Fig 1) as well as factors IXa, Xla, XIa. UFH has a short half-life (Table 1) so rapid reversal is achievable by stopping the infusion. 15 Protamine sulphate is licensed for reversal of UFH, acting by preventing its interaction with antithrombin. Protamine sulphate is given as a slow intravenous bolus at a dose calculated from the number of units of UFH received in the last 2 hours, with 1 mg protamine sulphate neutralising approximately 80–100 units of UFH. In excess, protamine itself acts as an anticoagulant. Protamine is derived from fish sperm and there is a risk of allergic reactions, especially in individuals with previous protamine exposure, fish allergies and following vasectomy.

Low molecular weight heparin

Low-molecular-weight heparins (LMWH) contain shorter polymers than UFH, and their interaction with antithrombin affects Xa more than thrombin. 16 Protamine sulphate is less effective at reversing anti-Xa activity than antithrombin activity but is recommended for LMWH reversal based on an absence of alternatives and evidence from animal studies and small retrospective studies. 18 Up to 8 hours from LMWH administration protamine sulphate 1 mg/100 units can be considered, with a further dose of 0.5 mg/100 units if there is ongoing bleeding. If LMWH was given over 8 hours earlier, lower doses may be used. 19

Fondaparinux

Fondaparinux is a synthetic pentasaccharide not a LMWH but is considered here as it is used in similar indications and has a similar mechanism of action, by promoting the interaction of antithrombin and factor Xa (Fig 1). Protamine sulphate has no activity against fondaparinux. Recombinant activated factor VII can be considered for critical bleeding, 20 but this is an unlicensed indication.

Direct thrombin antagonists

Dabigatran and argatroban are direct thrombin antagonists. Dabigatran is given as an oral pro-drug dabigatran etexilate. Argatroban is given intravenously, its main use being in heparin-induced thrombocytopenia. By inhibiting thrombin these drugs reduce the conversion of fibrinogen to fibrin (Fig 1). Argatroban has a short half-life of around 45 minutes – stopping the infusion and initiating general measures should achieve reversal.

There is a licensed antidote, idarucizumab, for rapid reversal of dabigatran for emergency surgery and procedures or in life-threatening or uncontrolled bleeding. It is an engineered antibody fragment that mimics structural features of thrombin to bind dabigatran with high affinity, without binding other thrombin substrates. 21 In an open-label study, idarucizumab rapidly and completely reversed laboratory measures of anticoagulation in patients taking dabigatran. 22

Factor Xa inhibitors

Rivaroxaban, apixaban and edoxaban act by inhibiting Xa (Fig 1). Minor bleeding should be managed using local measures and delaying the next dose or discontinuing the drug. For more severe bleeding, tranexamic acid and supportive measures should be used but there is no licensed reversal agent. For life-threatening bleeding PCC may be considered; 17 however, this is an unlicensed indication and should be discussed with a haematologist. The rationale is that elevation of factor levels above normal will promote haemostasis, but there is limited evidence to suggest an improvement in laboratory measures of clotting and in bleeding from studies in animals and healthy individuals. 23 Prospective cohort studies have reported effective haemostasis using PCC, with rates of thromboembolic complications comparable to patients receiving PCC for warfarin reversal. 20

What is the role of laboratory measurement?

Vitamin K antagonists and UFH are routinely monitored using the INR and APTT respectively. Anti-Xa activity is a measure of LMWH anticoagulant effect, which may guide protamine doses. 16 The effect of direct thrombin antagonists and factor Xa inhibitors on routine clotting tests, and the utility of these tests in guiding reversal of anticoagulation is more complex. Therapeutic ranges for vitamin K antagonists and UFH should not be used to interpret clotting results in the presence of other agents. Drug-specific assays may not be available in all laboratories or out of hours. It is important to inform the laboratory of the type of anticoagulant and the timing of the last dose. The effect on routine clotting tests can depend upon which laboratory reagents are used. 24 Furthermore, the degree of intra-individual variation in drug levels (between peak and trough levels) and the degree of variation between individuals taking therapeutic doses must be taken into account when interpreting drug levels. 25 Table 4 summarises possible interpretations of normal and prolonged PT, APTT and TT in the presence of thrombin antagonists and Xa inhibitors, and the commonest drug-specific assays for each agent.

Whether and when to restart anticoagulant drugs following reversal

The bleeding risk associated with restarting a drug must be balanced against the thrombotic risk while off anticoagulation. If haemostasis is secured following a procedure or an intervention for bleeding, a pragmatic approach is to restart anticoagulation following local bridging protocols and monitoring for further bleeding. 26 Often a prophylactic dose of LMWH or a direct oral anticoagulant (DOAC) can be started 6–8 hours post procedure. Decisions are more challenging following reversal for bleeding when no procedure to achieve haemostasis is performed, for example
in intracranial haemorrhage. For some patients, especially those with traumatic intracranial haemorrhage and a persistent risk of falls, consideration may be given to discontinuing anticoagulation. Data on the optimal time to reintroduce anticoagulation following intracranial haemorrhage is minimal and conflicting, with suggested falls, consideration may be given to discontinuing anticoagulation. Data on the optimal time to reintroduce anticoagulation following intracranial haemorrhage is minimal and conflicting, with suggested times ranging from 4–7 days\(^{26}\) to 10–30 weeks.\(^{27}\)

### Future prospects

Two ‘universal’ reversal agents are under development. Andexanet alfa, recently licensed in America, is a recombinant Xa modified to lack catalytic and membrane-binding activity but retain affinity to Xa inhibitors, LMWH, fondaparinux and antithrombin.\(^{28}\) It corrects laboratory measures of coagulation in patients with major bleeding taking direct Xa inhibitors or the LMWH enoxaparin. Rates of thrombosis are higher than in studies examining PCC, but it is unclear to what extent this reflects interruption of anticoagulation and underlying pathology.\(^{29}\) Ciraparantag is a synthetic molecule that binds UFH, LMWH, fondaparinux, Xa inhibitors and dabigatran. It has been examined in healthy volunteers given edoxaban where it corrected laboratory measures of clot formation.\(^{30}\)

### References

1. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008;99:807–18.
2. Czuprynska J, Patel JP, Ayia R. Current challenges and future prospects in oral anticoagulant therapy. Br J Haematol 2017;178:838–51.
3. Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ 2017;359:j3782.
4. Keeling D, Tait RC, Watson H on behalf of the British Committee of Standards for Haematology. Perioperative management of anticoagulation and antiplatelet therapy. Br J Haematol 2016;175:602–13.
5. Hunt BJ, Allard S, Keeling D et al. A practical guideline for the haematological management of major haemorrhage. Br J Haematol 2015;170:788–803.
6. CRASH 2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32.
7. National Institute for Health and Care Excellence. Blood transfusion quality standard [Q5138]. London: NICE, 2016.
8. Hunt BJ, Levi M. Urgent reversal of vitamin K antagonists. BMJ 2018;360:k424.
9. Keeling D, Baglin T, Tait C et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011;156:311–24.
10. Watson HG, Baglin T, Laudlow SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145–9.
11. Sarode R, Jr Milling TJ, Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, phase IIb study. Circulation 2013;128:1234–43.
12. Goldstein JN, Refaai MA, Milling TJ Jr et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015;385:2077–87.
13. Dentali F, Marchesi C, Giorgi Pierfranceschi M et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429–38.
14. Brekelmans MPA, Ginkel KV, Daams JG et al. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis 2017;44:118–29.
15. Hirsh J, Bauer KA, Donati MB et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). CHEST 2008;133(Suppl 6):1415–595.
16. van Veen JH Maclean RM, Hampton KK et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis 2011;22:565–70.
17. Makris M, Van Veen TJ Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013;160:35–66.
18. Scheie F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554–62.
19. Pollock CV Jr, Reilly PA, van Ryn J et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 2017;377:431–41.
20. Dickteite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014;111:189–98.

| Drug | PT | APTT | TT |
|------|----|------|----|
| Normal | Prolonged | Normal | Prolonged | Normal | prolonged |
| Dabigatran | Below or within therapeutic levels | Supratherapeutic levels | Below or within therapeutic levels | Within or above therapeutic levels | Likely little or no drug present | Cannot interpret |
| Rivaroxaban | Therapeutic levels unlikely but cannot be excluded | Therapeutic or supratherapeutic levels | Therapeutic or supratherapeutic levels | Unaffected | Not useful | Apixaban-specific anti Xa activity |
| Apixaban | Therapeutic levels cannot be excluded | Not useful | Unaffected | Unaffected | Edoxaban-specific anti Xa activity |

**Table 4. Effect of direct thrombin antagonists and Xa inhibitors on clotting tests, and drug-specific assays**

**Drug**

- Dabigatran
- Rivaroxaban
- Apixaban
- Edoxaban

**PT**

- Normal: Below or within therapeutic levels
- Prolonged: Supratherapeutic levels

**APTT**

- Normal: Below or within therapeutic levels
- Prolonged: Within or above therapeutic levels

**TT**

- Normal: Likely little or no drug present
- prolonged: Cannot interpret

**Drug specific assay**

- Dilute thrombin time or ecarin clotting time
- Unaffected
- Apixaban-specific anti Xa activity
- Edoxaban-specific anti Xa activity

**APTT = activated partial thromboplastin time; PT = prothrombin time; TT = thrombin time**
21 Majeed A, Agren A, Holmstrom M et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017;130:1706–12.
22 Albaladejo P, Samama CM, Sie P et al. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology 2017;127:111–20.
23 Kitchen S, Gray E, Mackie I, Baglin T, Makris M. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014;166:830–41.
24 Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016;172:315–36.
25 Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev 2017;31:77–84.
26 AlKherayf F, Xu Y, Gandara E et al. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. Thromb Res 2016;144:152–7.
27 Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010;41:2860–6.
28 Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446–51.
29 Connolly SJ, Milling TJ Jr, Eikelboom JW et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131–43.
30 Arseli JE, Bakhu SH, Laulicht BE et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017;117:238–45.
31 Hoffman M, Monroe DMI. A cell-based model of hemostasis. Thromb Haemost 2001;85:958–65.

Address for correspondence: Professor Mike Makris, Department of Haematology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK.
Email: m.makris@sheffield.ac.uk